

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
ALL	anand-naveen\$	1	<u>L29</u>
ALL	l27 and l26	88	<u>L28</u>
ALL	mhc	3097	<u>L27</u>
ALL	l25 and l24	224	<u>L26</u>
ALL	cd4	4024	<u>L25</u>
ALL	l23 and l22	454	<u>L24</u>
ALL	immun\$	113155	<u>L23</u>
ALL	(l20 or l21) and l19	458	<u>L22</u>
ALL	light chain	4201	<u>L21</u>
ALL	heavy chain	4228	<u>L20</u>
ALL	(l18 or l17) and l15	876	<u>L19</u>
ALL	genetic\$ engineer\$	13448	<u>L18</u>
ALL	recombina\$	66158	<u>L17</u>
ALL	(l1 or l2 or l3 or l4 or l5 or l6 or l8) adj50 l12 adj50 l10 adj50 l13	0	<u>L16</u>
ALL	(l1 or l2 or l3 or l4 or l5 or l6 or l8) and l12 and l10 and l13	936	<u>L15</u>
ALL	(l1 or l2 or l3 or l4 or l5 or l6 or l8) adj20 l12 adj20 l10 adj20 l13	0	<u>L14</u>
ALL	chimer\$	10059	<u>L13</u>
ALL	monoclon\$	33688	<u>L12</u>
ALL	antibod\$	90050	<u>L11</u>
ALL	conjugate	53266	<u>L10</u>
ALL	antigen	59495	<u>L9</u>
ALL	dendritic cell	756	<u>L8</u>
ALL	cell of von kupffer	0	<u>L7</u>
ALL	kupffer cell	384	<u>L6</u>
ALL	macrophage	12121	<u>L5</u>
ALL	langerhans cell	447	<u>L4</u>
ALL	monocyte	6802	<u>L3</u>
ALL	apc	4552	<u>L2</u>
ALL	antigen presenting cell	1306	<u>L1</u>

Search Results - Record(s) 1 through 1 of 1 returned.

1. Document ID: WO 9640941 A1

File: EPAB

Dec 19, 1996

Entry 1 of 1

PUB-NO: WO009640941A1

DOCUMENT-IDENTIFIER: WO 9640941 A1

TITLE: CHIMERIC ANTIBODIES FOR DELIVERY OF ANTIGENS TO SELECTED CELLS OF THE IMMUNE

SYSTEM

PUBN-DATE: December 19, 1996

INVENTOR-INFORMATION:

NAME	COUNTRY
ANAND, NAVEEN N	CA
BARBER, BRIAN H	CA
CATES, GEORGE C	CA
CATERINI, JUDITH E	CA
KLEIN, MICHEL H	CA

INT-CL (IPC): C12 N 15/62; C07 K 19/00; C12 N 15/13; C12 N 15/86; A61 K 39/385; G01 N 33/577; C12 P 21/08

EUR-CL (EPC): C12N015/62 ; C07K014/16 , C07K016/28

ABSTRACT:

Antibody molecules specific for surface structures of antigen presenting cells that have been modified to include an antigen moiety at a specific site therein to produce novel conjugate antibody molecules are disclosed. These conjugate molecules are produced by genetic modification of genes encoding light and heavy chains of the surface structure specific antibody, and expression in mammalian cells to produce the conjugate antibody. The conjugate antibody retained specificity for antigen presenting cells and contained the antigen moiety. The conjugate antibody molecules deliver the antigen to antigen presenting cells to produce an enhanced immune response to a host immunized therewith. The conjugate antibody molecules and nucleic acid molecules encoding them are useful as antigens and as immunogens in diagnostic and prophylactic applications.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | IOMC | Image

Term	Documents
ANAND-NAVEENS\$	0
ANAND-NAVEEN-N	1
ANAND-NAVEEN\$	1

Display 200 Documents

including document number

1

Search Results - Record(s) 1 through 88 of 88 returned.

1. Document ID: US 6004811 A

File: USPT

Dec 21, 1999

Entry 1 of 88

US-PAT-NO: 6004811

DOCUMENT-IDENTIFIER: US 6004811 A

TITLE: Redirection of cellular immunity by protein tyrosine kinase chimeras

DATE-ISSUED: December 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seed; Brian	Boston	MA	N/A	N/A
Romeo; Charles	Belmont	MA	N/A	N/A
Kolanus; Waldemar	Watertown	MA	N/A	N/A

US-CL-CURRENT: 435/372.3; 435/375, 435/6, 435/69.1, 536/23.4, 536/23.5

ABSTRACT:

Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.

23 Claims, 19 Drawing figures

Exemplary Claim Number: 1,5

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KINIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-------	-------

2. Document ID: US 6004781 A

File: USPT

Dec 21, 1999

Entry 2 of 88

US-PAT-NO: 6004781
DOCUMENT-IDENTIFIER: US 6004781 A

TITLE: Nucleic acid encoding Ig-CD4 fusion proteins

DATE-ISSUED: December 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seed; Brian	Boston	MA	N/A	N/A

US-CL-CURRENT: 435/69.7; 435/252.3, 435/320.1, 536/23.4

ABSTRACT:

The invention relates to a fusion protein which comprises an immunoglobulin of the IgM, IgG1 or IgG3 immunoglobulin class, wherein the variable region of the light or heavy chain has been replaced with CD4 or fragment thereof which is capable of binding to gp120. The invention also relates to an immunoglobulin-like molecule comprising the fusion protein of the invention together with an immunoglobulin light or heavy chain. The invention also relates to a method of treating HIV or SIV infection comprising administering the fusion proteins or immunoglobulin-like molecules of the invention to an animal. The invention also relates to assays for HIV or SIV comprising contacting a sample suspected of containing HIV or SIV gp120 with the immunoglobulin-like molecule or fusion protein of the invention, and detecting whether a complex is formed.

14 Claims, 0 Drawing figures

Exemplary Claim Number: 1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

3. Document ID: US 6004555 A

Dec 21, 1999

Entry 3 of 88

File: USPT

US-PAT-NO: 6004555

DOCUMENT-IDENTIFIER: US 6004555 A

TITLE: Methods for the specific coagulation of vasculature

DATE-ISSUED: December 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX	N/A	N/A
Edgington; Thomas S.	La Jolla	CA	N/A	N/A

US-CL-CURRENT: 424/181.1; 424/178.1, 424/180.1, 435/7.23, 530/381, 530/382, 530/383, 530/384, 530/391.7

ABSTRACT:

Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.

87 Claims, 11 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

4. Document ID: US 6001365 A

Dec 14, 1999

Entry 4 of 88

File: USPT

US-PAT-NO: 6001365
DOCUMENT-IDENTIFIER: US 6001365 A

TITLE: In vitro activation of cytotoxic T cells

DATE-ISSUED: December 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Peterson; Per A.	La Jolla	CA	N/A	N/A
Jackson; Michael	Del Mar	CA	N/A	N/A
Langlade-Demoyen; Pierre	Del Mar	CA	N/A	N/A

US-CL-CURRENT: 424/193.1; 424/197.11, 424/236.1, 435/348, 514/2, 514/21

ABSTRACT:

The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CD8 cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human .beta.2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.

1 Claims, 25 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMNC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

5. Document ID: US 5998171 A

File: USPT

Dec 7, 1999

Entry 5 of 88

US-PAT-NO: 5998171

DOCUMENT-IDENTIFIER: US 5998171 A

TITLE: Polynucleotides encoding human endokine alpha

DATE-ISSUED: December 7, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Darnestown	MD	N/A	N/A
Ni; Jian	Rockville	MD	N/A	N/A
Rosen; Craig A.	Laytonsville	MD	N/A	N/A

US-CL-CURRENT: 435/69.5; 435/252.3, 435/320.1, 435/69.1, 536/23.5, 536/24.3

ABSTRACT:

The present invention novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods concerning TNF family-related disorders.

99 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMNC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

6. Document ID: US 5994511 A

File: USPT

Nov 30, 1999

Entry 6 of 88

US-PAT-NO: 5994511
DOCUMENT-IDENTIFIER: US 5994511 A

TITLE: Anti-IgE antibodies and methods of improving polypeptides
DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lowman; Henry B.	El Granada	CA	N/A	N/A
Presta; Leonard G.	San Francisco	CA	N/A	N/A
Jardieu; Paula M.	San Mateo	CA	N/A	N/A
Lowe; John	Daly City	CA	N/A	N/A

US-CL-CURRENT: 530/387.3; 424/133.1, 424/135.1, 424/145.1, 424/810, 436/548, 530/388.25,

US-CL-PREV: 530/868

ABSTRACT:

The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

11 Claims, 21 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KOMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

7. Document ID: US 5993816 A

File: USPT

Entry 7 of 88

Nov 30, 1999

US-PAT-NO: 5993816
DOCUMENT-IDENTIFIER: US 5993816 A

TITLE: Methods to inhibit humoral immune responses, immunoglobulin production and B cell activation with 5c8-specific antibodies

DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lederman; Seth	New York	NY	N/A	N/A
Chess; Leonard	Scarsdale	NY	N/A	N/A
Yellin; Michael J.	Riverdale	NY	N/A	N/A

US-CL-CURRENT: 424/154.1; 424/130.1, 424/133.1, 424/141.1, 424/142.1, 424/143.1,
424/144.1, 424/153.1, 424/173.1, 530/387.1, 530/387.3, 530/388.1, 530/388.15, 530/388.2,
530/388.22, 530/388.7, 530/388.73, 530/388.75

ABSTRACT:

This invention provides an isolated nucleic acid molecule encoding a protein from the surface of activated T cells, wherein the protein is necessary for T cell activation of B cells. The nucleic acid molecule may include a DNA molecule or a cDNA molecule. This invention further provides a gene transfer vector including the nucleic acid molecule operably linked to a promoter of RNA transcription. The vector may be a plasmid or a viral vector. This invention further provides a host vector system including the gene transfer vector in a suitable host cell. The transformed yeast or a stably transformed mammalian cell. This invention further provides a method of producing a T cell surface protein necessary for T cell activation of B cells which includes growing the host vector system under conditions permitting production of the protein, followed by recovering the protein so produced. This invention further provides for methods to inhibit humoral immune responses, immunoglobulin production and B cell activation with 5C8-specific antibodies.

14 Claims, 63 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMTC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

8. Document ID: US 5989843 A

Nov 23, 1999

Entry 8 of 88

File: USPT

US-PAT-NO: 5989843

DOCUMENT-IDENTIFIER: US 5989843 A

TITLE: Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein

DATE-ISSUED: November 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gallatin; W. Michael	Mercer Island	WA	N/A	N/A
Vazeux; Rosemary	Seattle	WA	N/A	N/A

US-CL-CURRENT: 435/15; 435/4

ABSTRACT:

Modulators of protein kinase C phosphorylation of human intercellular adhesion molecule polypeptide (designated "ICAM-R") are identified through novel methods.

1 Claims, 39 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 34

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMTC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

9. Document ID: US 5985847 A

Nov 16, 1999

Entry 9 of 88

US-PAT-NO: 5985847

DOCUMENT-IDENTIFIER: US 5985847 A

TITLE: Devices for administration of naked polynucleotides which encode biologically active peptides

DATE-ISSUED: November 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Carson; Dennis A.	Del Mar	CA	N/A	N/A
Raz; Eyal	San Diego	CA	N/A	N/A

US-CL-CURRENT: 514/44; 424/278.1, 435/285.1, 604/46

ABSTRACT:

This invention relates to apparatus and compositions for administering antigens and immunostimulatory peptides to a mammalian host by the introduction of one or more naked polynucleotides to operatively encode for the antigens and immunostimulatory peptides, preferably by non-invasive means.

5 Claims, 39 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KOMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

10. Document ID: US 5980892 A

Nov 9, 1999

Entry 10 of 88

US-PAT-NO: 5980892

DOCUMENT-IDENTIFIER: US 5980892 A

TITLE: Monoclonal antibodies reactive with defined regions of the T cell antigen receptor

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skibbens; Robert V.	Chapel Hill	NC	N/A	N/A
Henry; Larry D.	Brookline	MA	N/A	N/A
Rittershaus; Charles W.	Malden	MA	N/A	N/A
Tian; Wei-Tao	Allston	MA	N/A	N/A
Ip; Stephen H.	Sudbury	MA	N/A	N/A
Kung; Patrick C.	Lexington	MA	N/A	N/A
Snider; Mary Ellen	Ledyard	CT	N/A	N/A
Ko; Jone-Long	Cambridge	MA	N/A	N/A
Wood; Nancy L.	Cambridge	MA	N/A	N/A

US-CL-CURRENT: 424/144.1; 424/154.1, 435/7.1, 435/7.24

ABSTRACT:

The present invention relates to monoclonal antibodies which recognize defined regions of the T-cell receptor (TCR). In a specific embodiment, the invention provides monoclonal antibodies which are reactive with a constant region of the alpha chain of the TCR. In particular embodiments, the invention relates to two monoclonal antibodies, termed .alpha.F1 and .alpha.F2, which react with two different epitopes on the framework region of the .alpha. monomer of the TCR molecule. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the beta chain of the TCR. In particular, the invention provides two monoclonal antibodies, termed W112 and 2D1, which react with .beta. chain variable regions V.beta.5.3 and V.beta.8.1, respectively. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the delta chain of the TCR. In particular, the invention provides monoclonal antibody .delta.TCS1, isotype IgG2a. The monoclonal

the invention provides monoclonal antibody .delta.TCS1, isotype IgG2a. The monoclonal antibodies of the invention have value in diagnosis and therapy and are useful tools for study of the immune system.
27 Claims, 31 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 26

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMTC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

11. Document ID: US 5977318 A

Nov 2, 1999

Entry 11 of 88

File: USPT

US-PAT-NO: 5977318

DOCUMENT-IDENTIFIER: US 5977318 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Hopewell	NJ	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A
Kiener; Peter A.	Edmonds	WA	N/A	N/A

US-CL-CURRENT: 530/388.1; 424/141.1, 424/143.1, 435/331, 435/334, 530/388.15, 530/388.73,
530/861, 530/866, 530/868

ABSTRACT:

The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.

4 Claims, 37 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 37

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMTC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

12. Document ID: US 5977303 A

Nov 2, 1999

Entry 12 of 88

File: USPT

US-PAT-NO: 5977303
DOCUMENT-IDENTIFIER: US 5977303 A

TITLE: Mammalian cell surface antigens

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aversa; Gregorio	Palo Alto	CA	N/A	N/A
Chang; Chia-Chun J.	San Jose	CA	N/A	N/A
Cocks; Benjamin G.	Mountain View	CA	N/A	N/A
de Vries; Jan E.	Los Altos	CA	N/A	N/A

US-CL-CURRENT: 530/350; 435/69.6, 435/69.7, 530/300

ABSTRACT:

Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigen. Methods of using said reagents and diagnostic kits are also provided.
30 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Data | Reference | Claims | KIMC | Image

13. Document ID: US 5976533 A
Entry 13 of 88

File: USPT

Nov 2, 1999

US-PAT-NO: 5976533
DOCUMENT-IDENTIFIER: US 5976533 A

TITLE: Monoclonal antibodies reactive with defined regions of the T cell antigen receptor

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skibbens; Robert V.	Chapel Hill	NC	N/A	N/A
Henry; Larry D.	Brookline	MA	N/A	N/A
Rittershaus; Charles W.	Malden	MA	N/A	N/A
Tian; Wei-Tao	Allston	MA	N/A	N/A
Ip; Stephen H.	Sudbury	MA	N/A	N/A
Kung; Patrick C.	Lexington	MA	N/A	N/A
Snider; Mary Ellen	Ledyard	CT	N/A	N/A
Ko; Jone-Long	Cambridge	MA	N/A	N/A
Wood; Nancy L.	Cambridge	MA	N/A	N/A

US-CL-CURRENT: 424/144.1; 435/70.21, 530/388.22, 530/388.75

ABSTRACT:

The present invention relates to monoclonal antibodies which recognize defined regions of the T-cell receptor (TCR). In a specific embodiment, the invention provides monoclonal antibodies which are reactive with a constant region of the alpha chain of the TCR. In particular embodiments, the invention relates to two monoclonal antibodies, termed .alpha.F1 and .alpha.F2, which react with two different epitopes on the framework region of the .alpha. monomer of the TCR molecule. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the beta chain of the TCR. In particular, the invention provides two monoclonal antibodies, termed W112 and 2D1, which react with .beta. chain variable regions V.beta.5.3 and V.beta.8.1, respectively. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the delta chain of the TCR. In particular, the invention provides monoclonal antibody .delta.TCS1, isotype IgG2a. The monoclonal antibodies of the invention have value in diagnosis and therapy and are useful tools for study of the immune system.
9 Claims, 31 Drawing figures

14. Document ID: US 5972334 A

Entry 14 of 88

File: USPT

Oct 26, 1999

US-PAT-NO: 5972334

DOCUMENT-IDENTIFIER: US 5972334 A

TITLE: Vaccines for treatment of lymphoma and leukemia

DATE-ISSUED: October 26, 1999

INVENTOR-INFORMATION:

NAME

Denney, Jr.; Dan W.

CITY

Redwood City

STATE

CA

ZIP CODE

N/A

COUNTRY

N/A

US-CL-CURRENT: 424/131.1, 424/141.1, 435/320.1, 435/325, 435/326, 435/327, 435/343.1,
435/372.3, 435/68.1, 435/69.7, 530/387.2, 536/23.53

ABSTRACT:

The present invention provides multivalent vaccines for the treatment of B-cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom vaccines, including multivalent vaccines for the treatment of immune cell tumors malignancies as well as methods of treating immune cell tumors using custom vaccines.

47 Claims, 26 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 26

15. Document ID: US 5969109 A

Entry 15 of 88

File: USPT

Oct 19, 1999

US-PAT-NO: 5969109

DOCUMENT-IDENTIFIER: US 5969109 A

TITLE: Chimeric antibodies comprising antigen binding sites and B and T cell epitopes

DATE-ISSUED: October 19, 1999

INVENTOR-INFORMATION:

NAME

Bona; Constantin

Zaghouni; Habib

CITY

New York

Knoxville

STATE

NY

TN

ZIP CODE

10022

37919

COUNTRY

N/A

N/A

US-CL-CURRENT: 530/387.3, 530/387.1, 530/388.1, 530/388.2, 530/388.73, 530/388.75

ABSTRACT:

The present invention relates to chimeric antibodies which comprise a B cell epitope, a T cell epitope, and/or an antigen binding site. The chimeric antibodies may be produced by replacing at least a portion of an immunoglobulin molecule with the desired epitope or antigen binding site such that the functional capabilities of the epitope and the parent immunoglobulin are retained. The chimeric antibodies of the invention may be used to enhance an immune response against pathogens and tumor cells in subjects in need of such treatment.

6 Claims, 51 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 33

Oct 19, 1999

16. Document ID: US 5968510 A

File: USPT

Entry 16 of 88

US-PAT-NO: 5968510

DOCUMENT-IDENTIFIER: US 5968510 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: October 19, 1999

INVENTOR-INFORMATION:

NAME

Linsley; Peter S.

Ledbetter; Jeffrey A.

Damle; Nitin K.

Brady; William

Kiener; Peter A.

	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Hopewell	NJ	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A
Kiener; Peter A.	Edmonds	WA	N/A	N/A

US-CL-CURRENT: 424/141.1, 424/139.1, 424/143.1, 424/154.1, 424/809, 424/810, 514/12,
514/2, 530/388.1, 530/388.15, 530/388.22, 530/388.73

ABSTRACT:

The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.

1 Claims, 37 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 37

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

17. Document ID: US 5962224 A

File: USPT

Entry 17 of 88

Oct 5, 1999

US-PAT-NO: 5962224
DOCUMENT-IDENTIFIER: US 5962224 A

TITLE: Isolated DNA encoding p62 polypeptides and uses therefor

DATE-ISSUED: October 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shin; Jaekyo	Westwood	MA	N/A	N/A
Joung; Insil	Boston	MA	N/A	N/A
Vadlamudi; Ratna K.	Norwood	MA	N/A	N/A
Strominger; Jack L.	Lexington	MA	N/A	N/A

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/366, 435/69.1, 435/70.1, 536/23.1,
536/24.31, 536/24.33

ABSTRACT:

Isolated nucleic acid molecules encoding novel members of the p62 family of polypeptides which include, in preferred embodiment, an SH2 binding domain and a ubiquitin binding domain are described. Also disclosed are novel members of the p160 family of polypeptides. The p62 polypeptides and the p160 polypeptides of the invention are capable of modulating leukocyte activity, e.g., by stimulating a B cell response, including B cell proliferation, B cell aggregation, B cell differentiation, B cell survival, and/or stimulating a T cell response, e.g., T cell proliferation, T cell aggregation, T cell differentiation, and T cell survival, are disclosed. The p62 polypeptides and the p160 polypeptides of the invention are also capable of modulating ubiquitin-mediated degradation of cellular proteins. In addition to isolated nucleic acids molecules, antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced are also described. The invention further provides isolated p62 polypeptides and isolated p160 polypeptides, fusion polypeptides and active fragments thereof. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

28 Claims, 32 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 52

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KMC | Image

18. Document ID: US 5961976 A

Entry 18 of 88

File: USPT

Oct 5, 1999

US-PAT-NO: 5961976

DOCUMENT-IDENTIFIER: US 5961976 A

TITLE: Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV

DATE-ISSUED: October 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wang; Chang Yi	Cold Spring Harbor	NY	N/A	N/A

US-CL-CURRENT: 424/173.1; 424/154.1, 530/388.75, 530/389.6

ABSTRACT:

This invention is directed to monoclonal antibodies produced by using CD4-expressing T lymphocytes, such as peripheral blood mononuclear T cells, thymocytes, splenocytes and leukemia or lymphoma derived T cell line cells such as HPB-ALL or SUP-T as the immunogen in accordance with the protocols and screening procedures described. The monoclonal antibodies of the present invention are characterized by their ability to neutralize in vitro and in vivo primary isolates of Human Immunodeficiency Virus (HIV) and related immunodeficiency viruses. The antibodies are directed against a host cell antigen complex comprising CD4 protein in association with domains from chemokine receptors and have broad neutralizing activities against primary isolates from all clades of HIV type 1 (HIV-1) and primary isolates of HIV type 2 (HIV-2) and Simian Immunodeficiency Virus (SIV). The present invention is also directed to a method of selecting and producing such antibodies, hybridomas which secrete such antibodies, pharmaceutical compositions comprising such antibodies and methods for pre- and post-exposure prevention of immunodeficiency virus infection in primates, including humans, by such antibodies whose primary targets are CD4 expressing lymphocytes.

26 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

19. Document ID: US 5955300 A

File: USPT

Sep 21, 1999

Entry 19 of 88

US-PAT-NO: 5955300

DOCUMENT-IDENTIFIER: US 5955300 A

TITLE: Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies

DATE-ISSUED: September 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Faure; Florence	Paris	N/A	N/A	FRX
Hercend; Thierry	Charenton le Pont	N/A	N/A	FRX
Huard; Bertrand	L'Haye les Roses	N/A	N/A	FRX
Triebel; Frederic	Versailles	N/A	N/A	FRX

US-CL-CURRENT: 435/69.1; 435/455, 530/324, 530/330, 530/350, 530/391.3, 530/391.7

ABSTRACT:

Soluble polypeptide fraction consisting of all or part one at least of the four immunoglobulin-type extracellular LAG-3 protein domains (amino acids 1-159, 160-230, 240-330 and 331-412 of the SEQ ID NO:1 sequence) or consisting of one peptide sequence derived from these domains by replacement, addition or deletion of one or more amino acids. The fraction of the invention has a specificity at least equal to that of LAG-3 in relation to its ligand.

10 Claims, 17 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 13

20. Document ID: US 5951983 A

File: USPT

Sep 14, 1999

Entry 20 of 88

US-PAT-NO: 5951983

DOCUMENT-IDENTIFIER: US 5951983 A

TITLE: Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies

DATE-ISSUED: September 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bazin; Herve	Brussels	N/A	N/A	BEX
Latinne; Dominique	Brussels	N/A	N/A	BEX
Kaplan; Ruth	Tewksbury	MA	N/A	N/A
Kieber-Emmons; Thomas	Newton Square	PA	N/A	N/A
Postema; Christina E.	Charlestown	MA	N/A	N/A
White-Scharf; Mary E.	Winchester	MA	N/A	N/A

US-CL-CURRENT: 424/154.1, 424/130.1, 424/133.1, 424/141.1, 424/143.1, 424/144.1,
424/153.1, 424/173.1, 435/328, 435/332, 435/343, 435/343.1, 435/343.2, 435/452,
435/69.6, 435/70.21, 530/387.1, 530/387.3, 530/388.1, 530/388.2, 530/388.22, 530/388.7,
530/388.73, 530/388.75, 536/23.53

ABSTRACT:

The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.

10 Claims, 82 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 53

21. Document ID: US 5929211 A

File: USPT

Jul 27, 1999

Entry 21 of 88

US-PAT-NO: 5929211
DOCUMENT-IDENTIFIER: US 5929211 A

TITLE: Carbohydrate-directed cross-linking reagents

DATE-ISSUED: July 27, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ashkenazi; Avi J.	San Mateo	CA	N/A	N/A
Chamow; Steven M.	San Mateo	CA	N/A	N/A
Kogan; Timothy P.	Sugar Land	TX	N/A	N/A

US-CL-CURRENT: 530/351; 424/178.1, 424/179.1, 424/194.1, 424/195.11, 424/85.1, 530/359,
530/380, 530/387.1, 530/389.1, 530/389.2, 530/391.1, 530/391.3, 530/391.5, 530/391.7,
530/391.9, 530/395, 530/396, 530/397, 530/398, 530/399, 548/544, 548/546

ABSTRACT:

The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.

17 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

22. Document ID: US 5928643 A

File: USPT

Jul 27, 1999

Entry 22 of 88

US-PAT-NO: 5928643

DOCUMENT-IDENTIFIER: US 5928643 A

TITLE: Method of using CD2-binding domain of lymphocyte function associated antigen 3 to initiate T cell activation

DATE-ISSUED: July 27, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wallner; Barbara P.	Cambridge	MA	N/A	N/A
Miller; Glenn T.	Haverhill	MA	N/A	N/A
Rosa; Margaret D.	Winchester	MA	N/A	N/A

US-CL-CURRENT: 424/134.1; 424/153.1, 424/173.1, 424/182.1, 424/185.1, 424/192.1,
435/69.7, 514/12, 530/324, 530/387.1

ABSTRACT:

Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.

4 Claims, 47 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 31

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

23. Document ID: US 5925351 A

File: USPT

Jul 20, 1999

Entry 23 of 88

US-PAT-NO: 5925351

DOCUMENT-IDENTIFIER: US 5925351 A

TITLE: Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

DATE-ISSUED: July 20, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Browning; Jeffrey L.	Brookline	MA	N/A	N/A
Benjamin; Christopher D.	Beverly	MA	N/A	N/A
Hochman; Paula S.	Brookline	MA	N/A	N/A

US-CL-CURRENT: 424/143.1, 424/144.1, 424/145.1, 424/156.1, 514/2, 514/8, 530/387.1,

530/388.22, 530/388.23, 530/388.73, 530/388.85, 530/389.2, 530/395

530/388.22, 530/388.23, 530/388.73, 530/388.85, 530/389.2, 530/395

ABSTRACT:

This invention relates to compositions and methods comprising "lymphotoxin-.beta. receptor blocking agents", which block lymphotoxin-.beta. receptor signalling. Lymphotoxin-.beta. receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-.beta. receptor extracellular domain that act as lymphotoxin-.beta. receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-.beta. receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-.beta. receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-.beta. receptor signalling is provided.

16 Claims, 7 Drawing figures

Exemplary Claim Number: 1,15

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMPC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

24. Document ID: US 5919456 A

File: USPT

Jul 6, 1999

Entry 24 of 88

US-PAT-NO: 5919456

DOCUMENT-IDENTIFIER: US 5919456 A

TITLE: IL-13 receptor specific chimeric proteins

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Puri; Raj K.	North Potomac	MD	N/A	N/A
Debinski; Waldemar	Hummelstown	PA	N/A	N/A
Pastan; Ira	Potomac	MD	N/A	N/A
Obiri; Nicholas	Gaithersberg	MD	N/A	N/A

US-CL-CURRENT: 424/181.1, 424/155.1, 424/183.1, 530/388.8, 530/391.7

14 Claims, 0 Drawing figures

Exemplary Claim Number: 1

This invention provides chimeric molecules useful for killing tumor cells bearing IL13 receptor(s) (IL-13R). The molecules comprise a cytotoxic molecule attached to a targeting molecule that specifically binds an IL-13 receptor. Preferred targeting molecules include IL-13 and anti-IL-13R antibodies.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMPC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

25. Document ID: US 5914111 A

Entry 25 of 88

US-PAT-NO: 5914111

DOCUMENT-IDENTIFIER: US 5914111 A

TITLE: CD2-binding domain of lymphocyte function associated antigen-3

DATE-ISSUED: June 22, 1999

File: USPT

Jun 22, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wallner; Barbara P.	Cambridge	MA	N/A	N/A
Miller; Glenn T.	Haverhill	MA	N/A	N/A
Rosa; Margaret D.	Winchester	MA	N/A	N/A

US-CL-CURRENT: 424/134.1; 424/153.1, 424/173.1, 424/182.1, 424/185.1, 424/192.1,
435/69.7, 514/12, 530/324, 530/387.1

ABSTRACT:

Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.

6 Claims, 47 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 31

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

26. Document ID: US 5912176 A

Entry 26 of 88

File: USPT

Jun 15, 1999

US-PAT-NO: 5912176

DOCUMENT-IDENTIFIER: US 5912176 A

TITLE: Antibodies against a host cell antigen complex for pre and post exposure

protection from infection by HIV

DATE-ISSUED: June 15, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wang; Chang Yi	Cold Spring Harbor	NY	N/A	N/A

US-CL-CURRENT: 435/452; 424/133.1, 424/154.1, 424/173.1, 435/343.2, 435/69.6, 435/70.21,
530/387.3, 530/388.75, 530/389.6

ABSTRACT:

This invention is directed to monoclonal antibodies produced by using CD4-expressing T lymphocytes, such as peripheral blood mononuclear T cells, thymocytes, splenocytes and leukemia or lymphoma derived T cell line cells such as HPB-ALL or SUP-T as the immunogen in accordance with the protocols and screening procedures described. The monoclonal antibodies of the present invention are characterized by their ability to neutralize in vitro and in vivo primary isolates of Human Immunodeficiency Virus (HIV) and related immunodeficiency viruses. The antibodies are directed against a host cell antigen complex comprising CD4 protein in association with domains from chemokine receptors and have broad neutralizing activities against primary isolates from all clades of HIV type 1 (HIV-1) and primary isolates of HIV type 2 (HIV-2) and Simian Immunodeficiency Virus (SIV). The present invention is also directed to a method of selecting and producing such antibodies, hybridomas which secrete such antibodies, pharmaceutical compositions comprising such antibodies and methods for pre- and post-exposure prevention of immunodeficiency virus infection in primates, including humans, by such antibodies whose primary targets are CD4 expressing lymphocytes.

94 Claims, 9 Drawing figures

Exemplary Claim Number: 1,39

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMTC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

27. Document ID: US 5912170 A

File: USPT

Jun 15, 1999

Entry 27 of 88

US-PAT-NO: 5912170
DOCUMENT-IDENTIFIER: US 5912170 A

TITLE: Redirection of cellular immunity by protein-tyrosine kinase chimeras

DATE-ISSUED: June 15, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seed; Brian	Boston	MA	N/A	N/A
Romeo; Charles	Belmont	MA	N/A	N/A
Kolanus; Waldemar	Watertown	MA	N/A	N/A

US-CL-CURRENT: 435/325; 435/352, 435/354, 435/366

ABSTRACT:

Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.

20 Claims, 19 Drawing figures

Exemplary Claim Number: 1,4

Number of Drawing Sheets: 11

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

28. Document ID: US 5889143 A

File: USPT

Mar 30, 1999

Entry 28 of 88

US-PAT-NO: 5889143

DOCUMENT-IDENTIFIER: US 5889143 A

TITLE: Evaluation and treatment of patients with progressive immunosuppression

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ochoa; Augusto C.	Frederick	MD	N/A	N/A
Longo; Dan L.	Kensington	MD	N/A	N/A
Ghosh; Paritosh	Frederick	MD	N/A	N/A
Young; Howard A.	Gaithersburg	MD	N/A	N/A

US-CL-CURRENT: 530/300; 530/358

ABSTRACT:

A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels, T lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, a protein in the T lymphocyte signal transduction pathway, or of the NF-.kappa.B/rel family and comparing the level and pattern to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.

2 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

29. Document ID: US 5889155 A

Mar 30, 1999

Entry 29 of 88

US-PAT-NO: 5889155

DOCUMENT-IDENTIFIER: US 5889155 A

TITLE: Carbohydrate-directed cross-linking reagents

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ashkenazi; Avi J.	San Mateo	CA	N/A	N/A
Chamow; Steven M.	San Mateo	CA	N/A	N/A
Kogan; Timothy P.	Sugar Land	TX	N/A	N/A

US-CL-CURRENT: 530/351; 424/178.1, 424/179.1, 424/194.1, 424/195.11, 424/85.1, 530/391.1, 530/391.3, 530/391.5, 530/391.7, 530/391.9, 530/395, 530/396, 530/397, 530/398

ABSTRACT:

The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.

18 Claims, 9 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 4

30. Document ID: US 5885796 A

Mar 23, 1999

Entry 30 of 88

US-PAT-NO: 5885796

DOCUMENT-IDENTIFIER: US 5885796 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: March 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Hopewell	NJ	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.1, 536/23.4, 536/23.5

ABSTRACT:

The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.

12 Claims, 43 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 37

31. Document ID: US 5885579 A

Mar 23, 1999

Entry 31 of 88

US-PAT-NO: 5885579

DOCUMENT-IDENTIFIER: US 5885579 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: March 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Hopewell	NJ	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A
Kiener; Peter A.	Edmonds	WA	N/A	N/A

US-CL-CURRENT: 424/192.1; 424/133.1, 424/141.1, 435/69.1, 435/69.7, 435/7.2, 514/12,
514/2, 530/350, 530/387.1, 530/866, 530/868

ABSTRACT:

The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.

11 Claims, 43 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 37

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

32. Document ID: US 5883223 A

Mar 16, 1999

Entry 32 of 88

US-PAT-NO: 5883223

DOCUMENT-IDENTIFIER: US 5883223 A

TITLE: CD9 antigen peptides and antibodies thereto

DATE-ISSUED: March 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gray; Gary S.	Brookline	MA	02146	N/A

US-CL-CURRENT: 530/328; 435/331, 435/334, 435/343, 435/343.1, 435/343.2, 435/346,
530/300, 530/324, 530/387.9, 530/388.2, 530/388.22, 530/388.7, 530/388.73, 530/388.75

ABSTRACT:

Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

6 Claims, 21 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 19

33. Document ID: US 5880268 A

File: USPT

Mar 9, 1999

Entry 33 of 88

US-PAT-NO: 5880268

DOCUMENT-IDENTIFIER: US 5880268 A

TITLE: Modulators of the interaction between ICAM-R and .alpha..sub.d /CD18

DATE-ISSUED: March 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gallatin; W. Michael	Seattle	WA	N/A	N/A
Vazeux; Rosemary	Seattle	WA	N/A	N/A

US-CL-CURRENT: 530/387.3; 530/387.9, 530/388.1, 530/388.22

ABSTRACT:

DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R. Specifically, antibody substances which modulate the interaction between ICAM-R and ad/CD18 are provided.

1 Claims, 39 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 34

34. Document ID: US 5877289 A

File: USPT

Mar 2, 1999

Entry 34 of 88

US-PAT-NO: 5877289

DOCUMENT-IDENTIFIER: US 5877289 A

TITLE: Tissue factor compositions and ligands for the specific coagulation of vasculature

DATE-ISSUED: March 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX	N/A	N/A
Edgington; Thomas S.	La Jolla	CA	N/A	N/A

US-CL-CURRENT: 530/387.1; 530/381, 530/387.3, 530/387.7, 530/387.9, 530/388.1, 530/388.22, 530/388.85, 530/391.7, 530/391.9

ABSTRACT:

Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.

100 Claims, 11 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

35. Document ID: US 5876950 A

Entry 35 of 88

US-PAT-NO: 5876950

DOCUMENT-IDENTIFIER: US 5876950 A

TITLE: Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy

DATE-ISSUED: March 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Siadak; Anthony W.	Seattle	WA	N/A	N/A
Hollenbaugh; Diane L.	Seattle	WA	N/A	N/A
Gilliland; Lisa K.	Bellevue	WA	N/A	N/A
Gordon; Marcia L.	Seattle	WA	N/A	N/A
Bajorath; Jurgen	Lynnwood	WA	N/A	N/A
Aruffo; Alejandro A.	Edmonds	WA	N/A	N/A

US-CL-CURRENT: 435/7.23; 424/133.1, 424/135.1, 424/144.1, 424/154.1, 435/343.2, 435/7.24,
530/387.3, 530/388.75

ABSTRACT:

The present invention provides monoclonal antibodies, antigen binding fragment and recombinant binding proteins specific for human gp39. These antibodies are specific for at least eight different epitopes on gp39. Hybridomas secreting specific antibodies which bind to these epitopes are also provided. Further, the present invention discloses the amino acid sequence of immunoglobulin light and heavy chain variable regions which bind to epitopes of gp39 and provide sFv and humanized antibodies which bind gp39. Also, provided are pharmaceutical compositions comprising the monoclonal antibodies, antigen binding fragments and recombinant binding proteins which bind gp39 and methods for using these compositions in diagnosing disease states, inhibiting B cell activation and for treating immunological disorders, such as autoimmune diseases, allergic responses, organ rejection and graft-versus-host disease. Antibodies of the present invention can also be used to image cells which express gp39 on their surface, such as tumor cells (e.g., lymphoma) and to target therapeutic agents to target cells.

50 Claims, 16 Drawing figures
 Exemplary Claim Number: 1
 Number of Drawing Sheets: 14

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KIWC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

36. Document ID: US 5871732 A

Entry 36 of 88

US-PAT-NO: 5871732
DOCUMENT-IDENTIFIER: US 5871732 A

TITLE: Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection

DATE-ISSUED: February 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Burkly; Linda C.	West Newton	MA	N/A	N/A
Chisholm; Patricia L.	Quincy	MA	N/A	N/A
Thomas; David W.	Wellsley	MA	N/A	N/A
Rosa; Margaret D.	Winchester	MA	N/A	N/A
Rosa; Joseph J.	Winchester	MA	N/A	N/A

US-CL-CURRENT: 424/133.1; 424/143.1, 424/154.1, 530/387.3, 530/388.75

ABSTRACT:

Anti-CD4 antibody homologs, DNA sequences and recombinant DNA molecules encoding them, prophylactic, immunotherapeutic and diagnostic compositions comprising those antibody homologs, and methods for preventing or treating diseases in mammals, including humans, caused by infective agents whose primary targets are CD4.sup.+ lymphocytes. Such diseases include acquired immune deficiency syndrome ("AIDS"), AIDS related complex, and human immunodeficiency virus infection.

21 Claims, 22 Drawing figures

Exemplary Claim Number: 1,16

Number of Drawing Sheets: 15

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMPC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

37. Document ID: US 5869050 A

Feb 9, 1999

Entry 37 of 88

US-PAT-NO: 5869050

DOCUMENT-IDENTIFIER: US 5869050 A

TITLE: Methods of blocking T-cell activation using anti-B7 monoclonal antibodies

DATE-ISSUED: February 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Boer; Mark	Almere	N/A	N/A	NLX
Conroy; Leah B.	Pacifica	CA	N/A	N/A

US-CL-CURRENT: 424/156.1; 424/133.1, 424/137.1, 424/141.1, 530/387.1, 530/387.5,
530/388.1, 530/388.85

ABSTRACT:

Methods for causing T cell anergy, treating allograft transplant rejection, treating graft versus host disease, and preventing or treating rheumatoid arthritis are presented, the methods comprising co-administration of a molecule that binds to the B7 antigen and an immunosuppressive agent.

28 Claims, 13 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMPC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

38. Document ID: US 5869262 A

Feb 9, 1999

Entry 38 of 88

File: USPT

US-PAT-NO: 5869262
DOCUMENT-IDENTIFIER: US 5869262 A

TITLE: Method for monitoring an inflammatory disease state by detecting circulating
ICAM-R

DATE-ISSUED: February 9, 1999

INVENTOR-INFORMATION:

NAME

Gallatin; W. Michael

Vazeux; Rosemary

CITY	STATE	ZIP CODE
Seattle	WA	N/A
Seattle	WA	N/A

COUNTRY
N/A
N/A

US-CL-CURRENT: 435/7.1; 435/7.92, 435/7.94, 435/7.95, 436/811

ABSTRACT:

Methods for monitoring the progression of systemic lupus erythematosus (SLE) in a patient by detecting elevated levels of circulating ICAM-R wherein progression is indicated in an SLE patient whose circulating ICAM-R levels are increased as compared to normal individuals or individuals with in active SLE. Methods for the detection of an inflammatory disease state selected from the group consisting of rheumatoid arthritis, SLE, and Guillain-Barre syndrome and multiple sclerosis in a patient by detecting elevated levels of circulating ICAM-R wherein the presence of the inflammatory disease state is indicated in a patient whose circulating ICAM-R levels are increased as compared to normal healthy individuals. ICAM-R is also known as ICAM-3 and CDw50 in the art.

4 Claims, 39 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 31

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

39. Document ID: US 5858358 A

Entry 39 of 88

File: USPT

Jan 12, 1999

US-PAT-NO: 5858358
DOCUMENT-IDENTIFIER: US 5858358 A

TITLE: Methods for selectively stimulating proliferation of T cells

DATE-ISSUED: January 12, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
June; Carl H.	Rockville	MD	N/A	N/A
Thompson; Craig B.	Chicago	IL	N/A	N/A
Nabel; Gary J.	Ann Arbor	MI	N/A	N/A
Gray; Gary S.	Brookline	MA	N/A	N/A
Rennert; Paul D.	Holliston	MA	N/A	N/A
Freeman; Gordon J.	Brookline	MA	N/A	N/A

US-CL-CURRENT: 424/130.1, 424/143.1, 424/154.1, 435/383, 530/387.1, 530/388.22,
530/388.7, 530/388.75

ABSTRACT:

Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28 or CD9, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

33 Claims, 48 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 23

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KOMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

40. Document ID: US 5859312 A

Entry 40 of 88

File: USPT

Jan 12, 1999

US-PAT-NO: 5859312
DOCUMENT-IDENTIFIER: US 5859312 A

TITLE: Transgenic non-human animals having targeting endogenous lymphocyte transduction genes and cognate human transgenes

DATE-ISSUED: January 12, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Littman; Daniel	San Francisco	CA	N/A	N/A
Sawada; Shinichiro	San Francisco	CA	N/A	N/A
Killeen; Nigel	San Francisco	CA	N/A	N/A

US-CL-CURRENT: 800/9; 435/7.1, 536/23.1, 800/18

ABSTRACT:

The invention provides transgenic non-human animals and transgenic non-human mammalian cells having at least one functionally disrupted lymphocyte transduction locus, particularly a CD4 locus, targeting constructs used to produce such transgenic stem cells and animals, methods and targeting constructs for inactivating or suppressing expression of endogenous lymphocyte transduction gene loci, transgenes encoding heterologous lymphocyte transduction proteins, and nonhuman animals that express a human lymphocyte transduction protein and lack expression of a cognate murine lymphocyte transduction protein.

8 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KIMC](#) | [Image](#)

41. Document ID: US 5821332 A

File: USPT

Oct 13, 1998

Entry 41 of 88

US-PAT-NO: 5821332

DOCUMENT-IDENTIFIER: US 5821332 A

TITLE: Receptor on the surface of activated CD4.sup.+ T-cells: ACT-4

DATE-ISSUED: October 13, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Godfrey; Wayne	Woodside	CA	N/A	N/A
Buck; David	Half Moon Bay	CA	N/A	N/A
Engleman; Edgar G.	Atherton	CA	N/A	N/A

US-CL-CURRENT: 530/350; 530/300, 530/324, 530/325, 530/326, 530/327, 530/328, 530/329,
530/330

ABSTRACT:

The invention provides purified ACT-4 receptor polypeptides, antibodies against these polypeptides and nucleic acids encoding ACT-4 receptor polypeptides. Also provided are methods of diagnosis and treatment using the same. ACT-4 receptors are preferentially expressed on the surface of activated CD4.sup.+ T-cells. ACT-4 receptors are usually expressed at low levels on the surface of activated CD8.sup.+ cells, and are usually substantially absent on resting T-cells, and on monocytes and B-cells (resting or activated). An exemplary ACT-4 receptor, termed ACT-4-h-1, has a signal sequence, an extracellular domain comprising three disulfide-bonded intrachain loops, a transmembrane domain, and an intracellular domain.

7 Claims, 18 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 9

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KIMC](#) | [Image](#)

42. Document ID: US 5817515 A

Oct 6, 1998

Entry 42 of 88

US-PAT-NO: 5817515

DOCUMENT-IDENTIFIER: US 5817515 A

TITLE: Human B2 integrin alpha subunit antibodies

DATE-ISSUED: October 6, 1998

INVENTOR-INFORMATION:

NAME

Gallatin; W. Michael

Van der Vieren; Monica

CITY

Mercer Island

Seattle

STATE

WA

ZIP CODE

N/A

COUNTRY

N/A

N/A

US-CL-CURRENT: 435/343.2, 435/325, 435/326, 435/332, 435/334, 435/343, 435/343.1,
435/346, 435/70.21, 530/387.1, 530/387.9, 530/388.1, 530/388.2, 530/388.22, 530/388.7,
530/388.73, 530/388.75

ABSTRACT:

Monoclonal antibodies, and hybridomas that express the antibodies, which are immunospecific for a novel human .beta..sub.2 integrin alpha subunit polypeptide are disclosed.

2 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

43. Document ID: US 5817311 A

File: USPT

Oct 6, 1998

Entry 43 of 88

US-PAT-NO: 5817311

DOCUMENT-IDENTIFIER: US 5817311 A

TITLE: Methods of inhibiting T-cell mediated immune responses with LO-CD2a-specific antibodies

DATE-ISSUED: October 6, 1998

INVENTOR-INFORMATION:

NAME

Bazin; Herve

Latinne; Dominique

CITY

Brussels

Brussels

STATE

N/A

N/A

ZIP CODE

N/A

N/A

COUNTRY

BEX

BEX

US-CL-CURRENT: 424/154.1, 424/130.1, 424/133.1, 424/141.1, 424/144.1, 424/153.1,
424/173.1, 435/332, 435/334, 435/343.1, 435/343.2, 530/388.2, 530/388.22, 530/388.73,
530/388.75

ABSTRACT:

The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.

14 Claims, 82 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 53

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Image

44. Document ID: US 5854070 A

File: USPT

Dec 29, 1998

Entry 44 of 88

US-PAT-NO: 5854070
DOCUMENT-IDENTIFIER: US 5854070 A

TITLE: Murine and humanizer 23F2G antibodies and cell lines expressing said antibodies
DATE-ISSUED: December 29, 1998

INVENTOR- INFORMATION:	CITY	STATE	ZIP CODE	COUNTRY
NAME Rose; Lynn M.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 435/343.2, 435/326, 435/328, 435/334, 435/343, 435/343.1, 435/346,
435/358, 530/387.1, 530/387.3, 530/388.1, 530/388.2, 530/388.22, 530/388.7, 530/388.73,
530/388.75

ABSTRACT:

Disclosed are methods for the alleviation of symptoms associated with inflammatory disease states, and more particularly to the inhibition of inflammatory processes associated with the multiple sclerosis disease, by administering a pharmaceutically effective amount of antibody substance immunologically reactive with the common beta chain (CD18) of human leukocyte integrins and/or competes with mAb 60.3 for binding to human LFA-1.

6 Claims, 19 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KIWC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

Dec 22, 1998

45. Document ID: US 5851828 A

File: USPT

Entry 45 of 88

US-PAT-NO: 5851828

DOCUMENT-IDENTIFIER: US 5851828 A

TITLE: Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells

DATE-ISSUED: December 22, 1998

INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seed; Brian	Boston	MA	N/A	N/A
Banapour; Babak	Boston	MA	N/A	N/A
Romeo; Charles	Belmont	MA	N/A	N/A
Kolanus; Waldemar	Watertown	MA	N/A	N/A

US-CL-CURRENT: 435/328; 424/93.21, 435/320.1, 435/366, 435/367, 435/372.3, 536/23.4,
536/23.53

ABSTRACT:

Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.

15 Claims, 56 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 27

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KIWC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

Dec 22, 1998

46. Document ID: US 5851795 A

File: USPT

Entry 46 of 88

US-PAT-NO: 5851795
DOCUMENT-IDENTIFIER: US 5851795 A

TITLE: Soluble CTLA4 molecules and uses thereof

DATE-ISSUED: December 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Hopewell	NJ	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A
Kiener; Peter A.	Edmonds	WA	N/A	N/A

US-CL-CURRENT: 435/69.1, 435/252.3, 435/320.1, 435/325, 435/69.7, 530/350, 530/367,

530/387.3, 536/23.1, 536/23.4

ABSTRACT:

The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.

21 Claims, 43 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 37

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

47. Document ID: US 5844095 A

File: USPT

Dec 1, 1998

Entry 47 of 88

US-PAT-NO: 5844095

DOCUMENT-IDENTIFIER: US 5844095 A

TITLE: CTLA4 Ig fusion proteins

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A
Damle; Nitin K.	Hopewell	NJ	N/A	N/A
Brady; William	Bothell	WA	N/A	N/A

US-CL-CURRENT: 530/387.3; 424/134.1, 424/192.1, 435/69.7

ABSTRACT:

The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.

2 Claims, 43 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 37

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

48. Document ID: US 5843728 A

Entry 48 of 88

US-PAT-NO: 5843728

DOCUMENT-IDENTIFIER: US 5843728 A

TITLE: Redirection of cellular immunity by receptor chimeras

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seed; Brian	Boston	MA	N/A	N/A
Romeo; Charles	Belmont	MA	N/A	N/A
Kolanus; Waldemar	Watertown	MA	N/A	N/A

US-CL-CURRENT: 435/70.1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.1

ABSTRACT:

Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.

55 Claims, 45 Drawing figures

Exemplary Claim Number: 32

Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMPC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

49. Document ID: US 5831029 A

Nov 3, 1998

Entry 49 of 88

US-PAT-NO: 5831029

DOCUMENT-IDENTIFIER: US 5831029 A

TITLE: Human .beta.2 integrin .alpha. subunit

DATE-ISSUED: November 3, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gallatin; W. Michael	Mercer Island	WA	N/A	N/A
Van der Vieren; Monica	Seattle	WA	N/A	N/A

US-CL-CURRENT: 530/387.2; 435/331, 435/334, 435/346, 530/387.9, 530/388.1, 530/388.22,
530/388.7, 530/389.6

ABSTRACT:

DNA encoding a novel human .beta..sub.2 integrin .alpha. subunit polypeptide, designated .alpha..sub.d, is disclosed along with methods and materials for production of the same by recombinant procedures. Fusion proteins are also disclosed which include extracellular .alpha..sub.d protein fragments, .alpha..sub.d I domain fragments or full length .alpha..sub.d polypeptides and human immunoglobulin constant regions. Binding molecules specific for .alpha..sub.d are also disclosed as useful for modulating the biological activities of .alpha..sub.d. DNA from other species which show homology to human .alpha..sub.d encoding sequences are also disclosed.

10 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMPC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

50. Document ID: US 5830877 A

Nov 3, 1998

Entry 50 of 88

US-PAT-NO: 5830877
DOCUMENT-IDENTIFIER: US 5830877 A

TITLE: Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory

DATE-ISSUED: November 3, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Carson; Dennis A.	Del Mar	CA	N/A	N/A
Raz; Eyal	San Diego	CA	N/A	N/A

US-CL-CURRENT: 514/44; 536/23.5, 536/23.51, 536/23.52, 536/24.5

ABSTRACT:

This invention relates to methods for administering antigens and immunostimulatory peptides to a mammalian host by the introduction of one or more naked polynucleotides to operatively encode for the antigens and immunostimulatory peptides, preferably by non-invasive means.

23 Claims, 39 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 20

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KIMC](#) | [Image](#)

51. Document ID: US 5837243 A

File: USPT

Nov 17, 1998

Entry 51 of 88

US-PAT-NO: 5837243

DOCUMENT-IDENTIFIER: US 5837243 A

TITLE: Therapeutic compounds comprised of anti-Fc receptor antibodies

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deo; Yashwant M.	Audubon	PA	N/A	N/A
Goldstein; Joel	Edison	NJ	N/A	N/A
Graziano; Robert	Frenchtown	NJ	N/A	N/A
Somasundaram; Chezian	Allentown	PA	N/A	N/A

US-CL-CURRENT: 424/136.1; 424/134.1, 424/135.1, 424/184.1, 424/192.1, 424/277.1, 512/12,
530/387.3

ABSTRACT:

Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.

18 Claims, 49 Drawing figures
Exemplary Claim Number: 1,10
Number of Drawing Sheets: 29

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KIMC](#) | [Image](#)

52. Document ID: US 5837242 A

File: USPT

Nov 17, 1998

Entry 52 of 88

US-PAT-NO: 5837242
DOCUMENT-IDENTIFIER: US 5837242 A

TITLE: Multivalent and multispecific binding proteins, their manufacture and use
DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Holliger; Kaspar-Philipp	Cambridge	N/A	N/A	GBX	
Griffiths; Andrew David	Cambridge	N/A	N/A	GBX	
Hoogenboom; Hendricus	Hasselt	N/A	N/A	BEX Jacobus Matheus	Upsala N/A N/A SEX
Renerus	Kensington	CA	N/A	N/A	
Malmqvist; Magnus	Cambridge	N/A	N/A	GBX	
Marks; James David	Cambridge	N/A	N/A	GBX	
McGuinness; Brian Timothy	Cambridge	N/A	N/A	GBX	
Pope; Anthony Richard	Cambridge	N/A	N/A	GBX	
Prospero; Terence Derek	Cambridge	N/A	N/A	GBX	
Winter; Gregory Paul					

US-CL-CURRENT: 424/136.1, 435/320.1, 435/328, 435/69.7, 530/387.3, 530/412, 530/413,
536/23.4, 536/24.1

ABSTRACT:

Polypeptides comprising a first domain, which comprises a binding region of an immunoglobulin heavy chain variable region, and a second domain, which comprises a binding region of an immunoglobulin light chain variable region, the domains being linked but incapable of associating with each other to form an antigen binding site, associate to form antigen binding multimers, such as dimers, which may be multivalent or have multispecificity. The domains may be linked by a short peptide linker or may be joined directly together. Bispecific dimers may have longer linkers. Methods of preparation of the polypeptides and multimers and diverse repertoires thereof, and their display on the surface of bacteriophage for easy selection of binders of interest, are disclosed, along with many utilities.

85 Claims, 52 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 28

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMPC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

53. Document ID: US 5837478 A

File: USPT

Nov 17, 1998

Entry 53 of 88

US-PAT-NO: 5837478

DOCUMENT-IDENTIFIER: US 5837478 A

TITLE: Method of identifying modulators of binding between and VCAM-1

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Gallatin; W. Michael	Mercer Island	WA	N/A	N/A	
Van der Vieren; Monica	Seattle	WA	N/A	N/A	

US-CL-CURRENT: 435/7.24, 435/7.1, 435/7.2, 435/7.21, 435/7.8

ABSTRACT:

Methods to identify modulators of .alpha..sub.d binding to VCAM-1 are disclosed.

4 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMPC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

54. Document ID: US 5837460 A

Entry 54 of 88

File: USPT

Nov 17, 1998

US-PAT-NO: 5837460

DOCUMENT-IDENTIFIER: US 5837460 A

TITLE: Methods of identifying biologically active receptor-binding peptides

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Von Feldt; Joan M.	Wilmington	DE	N/A	N/A
Kieber-Emmons; Thomas	Newtown Square	PA	N/A	N/A
Weiner; David B.	Merion	PA	N/A	N/A
Williams; William V.	Havertown	PA	N/A	N/A

US-CL-CURRENT: 435/6; 435/7.1, 435/70.1, 435/71.1, 435/71.2, 435/965, 436/547

ABSTRACT:

A method of identifying peptides which mimic biologically active proteins is disclosed. The method comprises the steps of making a recombinant antibody library from genetic material obtained from an animal which has been immunized against antibodies that bind to the biological active protein to the mimicked. Recombinant antibodies are screened to identify antibodies which compete with the biological active protein. Peptides which comprise the recombinant antibody's CDR sequences are synthesized. Synthetic peptides which mimic GM-CSF are also disclosed.

13 Claims, 23 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KIMC](#) | [Image](#)

55. Document ID: US 5837822 A

Entry 55 of 88

File: USPT

Nov 17, 1998

US-PAT-NO: 5837822

DOCUMENT-IDENTIFIER: US 5837822 A

TITLE: Humanized antibodies specific for ICAM related protein

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gallatin; W. Michael	Seattle	WA	N/A	N/A
Vazeux; Rosemary	Seattle	WA	N/A	N/A

US-CL-CURRENT: 530/387.3; 530/388.1, 530/388.22

ABSTRACT:

DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R. More specifically, humanized antibodies specific for ICAM-R proteins are disclosed.

3 Claims, 39 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 31

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KIMC](#) | [Image](#)

Oct 27, 1998

56. Document ID: US 5827737 A

File: USPT

Entry 56 of 88

US-PAT-NO: 5827737

DOCUMENT-IDENTIFIER: US 5827737 A

TITLE: In vitro activation of cytotoxic T cells

DATE-ISSUED: October 27, 1998

INVENTOR-INFORMATION:

NAME

Peterson; Per A.

Jackson; Michael

Langlade-Demoyen; Pierre

CITY	STATE	ZIP CODE
La Jolla	CA	N/A
Del Mar	CA	N/A
Del Mar	CA	N/A

COUNTRY

N/A

N/A

N/A

US-CL-CURRENT: 435/348; 435/346, 530/394

ABSTRACT:

The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CD8 cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human .beta.2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.

1 Claims, 25 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

Sep 29, 1998

57. Document ID: US 5814318 A

File: USPT

Entry 57 of 88

US-PAT-NO: 5814318
DOCUMENT-IDENTIFIER: US 5814318 A

TITLE: Transgenic non-human animals for producing heterologous antibodies

DATE-ISSUED: September 29, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lonberg; Nils	San Francisco	CA	N/A	N/A
Kay; Robert M.	San Francisco	CA	N/A	N/A

US-CL-CURRENT: 424/184.1; 435/69.6, 530/387.1, 536/23.1, 536/23.53, 800/6

ABSTRACT:

The invention relates to transgenic non-human animals capable of producing heterologous antibodies and transgenic non-human animals having inactivated endogenous immunoglobulin genes. In one aspect of the invention, endogenous immunoglobulin genes are suppressed by antisense polynucleotides and/or by antiserum directed against endogenous immunoglobulins. Heterologous antibodies are encoded by immunoglobulin genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences of unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of functionally rearranging transgenic immunoglobulin sequences and producing a repertoire of antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g., by fusing with an immortalizing cell line such as a myeloma or by manipulating such B-cells by other techniques to perpetuate a cell line capable of producing a monoclonal heterologous antibody. The invention also relates to heavy and light chain immunoglobulin transgenes for making such transgenic non-human animals as well as methods and vectors for disrupting endogenous immunoglobulin loci in the transgenic animal.

10 Claims, 71 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 63

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMNC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

58. Document ID: US 5811517 A

File: USPT

Sep 22, 1998

Entry 58 of 88

US-PAT-NO: 5811517

DOCUMENT-IDENTIFIER: US 5811517 A

TITLE: ICAM-related protein variants

DATE-ISSUED: September 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gallatin; W. Michael	Seattle	WA	N/A	N/A
Vazeux; Rosemary	Seattle	WA	N/A	N/A

US-CL-CURRENT: 530/350; 435/252.3, 435/320.1, 435/325, 435/69.1, 435/69.7, 536/23.1, 536/23.4

ABSTRACT:

DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.

8 Claims, 39 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 34

59. Document ID: US 5807714 A

Entry 59 of 88

US-PAT-NO: 5807714

DOCUMENT-IDENTIFIER: US 5807714 A

TITLE: Method of production of antigen-specific glycosylation inhibiting factor

DATE-ISSUED: September 15, 1998

File: USPT

Sep 15, 1998

INVENTOR-INFORMATION:

NAME
Ishizaka, Kimishige
Ishii, Yasuyuki

CITY	STATE	ZIP CODE	COUNTRY
La Jolla	CA	N/A	N/A
La Jolla	CA	N/A	N/A

US-CL-CURRENT: 435/69.5; 435/69.7, 435/70.3

ABSTRACT:

A method for the recombinant production and for the isolation of antigen-specific glycosylation inhibiting factor (AgGIF) is provided. Also disclosed is a method for modulating the immune responses in an antigen-specific manner utilizing a AgGIF, comprising soluble non-specific GIF-TCR.alpha. chains which bind to the antigen, and which suppress the immune response in an antigen-specific fashion.

20 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

60. Document ID: US 5807734 A

Entry 60 of 88

File: USPT

Sep 15, 1998

US-PAT-NO: 5807734
DOCUMENT-IDENTIFIER: US 5807734 A

TITLE: Monoclonal antibodies and FV specific for CD2 antigen
DATE-ISSUED: September 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Diegel; Michael L.	Kent	WA	N/A	N/A
Linsley; Peter S.	Seattle	WA	N/A	N/A
Gilliland; Lisa K.	Seattle	WA	N/A	N/A
Moran; Patricia A.	Seattle	WA	N/A	N/A
Zarling; Joyce M.	Seattle	WA	N/A	N/A
Ledbetter; Jeffrey A.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 435/252.33; 424/134.1, 424/135.1, 424/192.1, 435/320.1, 435/70.21, 514/44,
530/387.3, 530/388.22, 536/23.53

ABSTRACT:

An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric monoclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional, non-HIV-1-producing T cells in the patient.

2 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMPC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

61. Document ID: US 5795572 A

File: USPT

Entry 61 of 88

Aug 18, 1998

US-PAT-NO: 5795572
DOCUMENT-IDENTIFIER: US 5795572 A

TITLE: Monoclonal antibodies and FV specific for CD2 antigen
DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Diegel, Michael L.	Kent	WA	N/A	N/A
Linsley, Peter S.	Seattle	WA	N/A	N/A
Gilliland, Lisa K.	Seattle	WA	N/A	N/A
Moran, Patricia A.	Seattle	WA	N/A	N/A
Zarling, Joyce M.	Seattle	WA	N/A	N/A
Ledbetter, Jeffrey A.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 424/135.1; 424/133.1, 424/141.1, 424/143.1, 424/154.1, 424/156.1,
424/178.1, 530/387.3, 530/388.1, 530/388.22, 530/391.3

ABSTRACT:

An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric monoclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional, non-HIV-1-producing T cells in the patient.

24 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KMC | Image |

62. Document ID: US 5776746 A

File: USPT

Jul 7, 1998

Entry 62 of 88

US-PAT-NO: 5776746

DOCUMENT-IDENTIFIER: US 5776746 A

TITLE: Gene amplification methods

DATE-ISSUED: July 7, 1998

INVENTOR-INFORMATION:

NAME

Denney, Jr.; Dan W.

CITY	STATE	ZIP CODE	COUNTRY
Lebanon	TN	N/A	N/A

US-CL-CURRENT: 435/464; 435/325, 435/355, 435/356, 435/358

ABSTRACT:

The present invention provides improved methods for the amplification and expression of recombinant genes in cells. The methods of the present invention permit the isolation of cell lines which have co-amplified input recombinant sequences which encode an amplifiable marker, one or more expression vectors encoding a protein of interest and optionally a selectable marker. The present methods allow the efficient isolation of amplified cell lines which express the protein(s) of interest in a relatively short period of time. The present invention also provides compositions comprising amplified T lymphoid cell lines.

98 Claims, 20 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

63. Document ID: US 5773218 A

Jun 30, 1998

Entry 63 of 88

US-PAT-NO: 5773218

DOCUMENT-IDENTIFIER: US 5773218 A

TITLE: Method to identify compounds which modulate ICAM-related protein interactions

DATE-ISSUED: June 30, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gallatin; W. Michael	Seattle	WA	N/A	N/A
Vazeux; Rosemary	Seattle	WA	N/A	N/A

US-CL-CURRENT: 435/6

ABSTRACT:

DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.

2 Claims, 39 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 34

64. Document ID: US 5770429 A

Jun 23, 1998

Entry 64 of 88

US-PAT-NO: 5770429

DOCUMENT-IDENTIFIER: US 5770429 A

TITLE: Transgenic non-human animals capable of producing heterologous antibodies

DATE-ISSUED: June 23, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lonberg; Nils	Redwood City	CA	N/A	N/A
Kay; Robert M.	San Francisco	CA	N/A	N/A

US-CL-CURRENT: 1/1; 424/184.1, 435/69.1, 530/387.1, 530/388.1, 530/388.15, 530/388.2, 536/23.1, 536/23.53, 800/6

ABSTRACT:

The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.

16 Claims, 112 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 93

65. Document ID: US 5766947 A

Jun 16, 1998

Entry 65 of 88

File: USPT

US-PAT-NO: 5766947
DOCUMENT-IDENTIFIER: US 5766947 A

TITLE: Monoclonal antibodies reactive with an epitope of a V.beta.3.1 variable region of a T cell receptor

DATE-ISSUED: June 16, 1998

INVENTOR- INFORMATION:	CITY	STATE	ZIP CODE	COUNTRY
NAME	Malden	MA	N/A	N/A
Rittershaus; Charles W.	Lexington	MA	N/A	N/A
Kung; Patrick C.	Wayland	MA	N/A	N/A
Jones; Nancy				

US-CL-CURRENT: 435/334; 424/142.1, 424/144.1, 435/343.2, 435/346, 514/825, 530/387.1,
530/387.9, 530/388.1, 530/388.15, 530/388.22, 530/388.75, 530/809

ABSTRACT:

The invention is directed to monoclonal antibodies reactive with a member of the V.beta.3 family variable region of the beta chain of the TCR. More particularly, the invention provides for detection of the V.beta.3.1 subfamily. In a specific embodiment the invention provides for detection of V.beta.3.1, without cross-reacting with other V.beta.3 family variable regions. In a specific embodiment, the monoclonal antibodies of the invention do not react with V.beta.3.2. In particular, the invention provides monoclonal antibodies, termed 5E4 and 8F10, which react with the variable region of a member of the V.beta.3 family. In various embodiments of the invention, these antibodies, or fragments or derivatives thereof, can be used to bind with a member of the V.beta.3 family TCR variable region amino acid sequences, either as part of an intact TCR or peptide, or T cell-surface molecule, or a fragment thereof. The monoclonal antibodies are useful for diagnosis and therapy of autoimmune disease, in particular rheumatoid arthritis.

11 Claims, 19 Drawing figures

Exemplary Claim Number: 1, 2

Number of Drawing Sheets: 9

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

66. Document ID: US 5741488 A

File: USPT

Apr 21, 1998

Entry 66 of 88

US-PAT-NO: 5741488

DOCUMENT-IDENTIFIER: US 5741488 A

TITLE: Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies

DATE-ISSUED: April 21, 1998

INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Feldman; Marc	London	N/A	N/A	GB2
Maini; Ravinder N.	London	N/A	N/A	GB2
Williams; Richard O.	London	N/A	N/A	GB2

US-CL-CURRENT: 424/154.1; 424/130.1, 424/141.1, 424/143.1, 424/144.1, 424/145.1,
424/153.1, 424/158.1, 424/173.1

ABSTRACT:

A method for treating autoimmune or inflammatory diseases, through the administration of anti-CD4 antibody in conjunction with or sequentially to anti-TNF antibody, is disclosed. The method can be used to aid in therapy for humans and other mammals with a wide variety of autoimmune or inflammatory diseases.

6 Claims, 6 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

67. Document ID: US 5730979 A

Mar 24, 1998

Entry 67 of 88

US-PAT-NO: 5730979

DOCUMENT-IDENTIFIER: US 5730979 A

TITLE: LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation

DATE-ISSUED: March 24, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bazin; Herve	Brussels	N/A	N/A	BEX
Latinne; Dominique	Brussels	N/A	N/A	BEX

US-CL-CURRENT: 424/154.1; 424/133.1, 424/143.1, 424/144.1, 424/153.1, 424/173.1, 435/332, 435/334, 435/343, 435/343.2, 435/70.21, 530/387.3, 530/388.22, 530/388.7, 530/388.73, 530/388.75

ABSTRACT:

The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.

19 Claims, 87 Drawing figures

Exemplary Claim Number: 1,6
Number of Drawing Sheets: 53

68. Document ID: US 5728677 A

Mar 17, 1998

Entry 68 of 88

US-PAT-NO: 5728677

DOCUMENT-IDENTIFIER: US 5728677 A

TITLE: Methods of inhibiting T-cell dependent proliferation of peripheral blood lymphocytes using the CD2-binding domain of lymphocyte function associated antigen 3

DATE-ISSUED: March 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wallner; Barbara P.	Cambridge	MA	N/A	N/A
Miller; Glenn T.	Haverhill	MA	N/A	N/A
Rosa; Margaret D.	Winchester	MA	N/A	N/A

US-CL-CURRENT: 514/12; 424/185.1, 424/809, 514/13, 514/15, 530/868

ABSTRACT:

Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.

9 Claims, 47 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 31

69. Document ID: US 5728533 A

Mar 17, 1998

Entry 69 of 88

US-PAT-NO: 5728533

DOCUMENT-IDENTIFIER: US 5728533 A

TITLE: Human .beta..sub.2 integrin .alpha..subunit

DATE-ISSUED: March 17, 1998

INVENTOR-INFORMATION:

NAME

Gallatin; W. Michael

Van der Vieren; Monica

CITY

Mercer Island

Seattle

STATE

WA

WA

ZIP CODE

N/A

N/A

COUNTRY

N/A

N/A

US-CL-CURRENT: 435/7.1; 435/7.8, 530/350, 530/380

ABSTRACT:

DNA encoding a novel human .beta..sub.2 integrin .alpha..subunit polypeptide, designated .alpha..sub.d, is disclosed along with methods and materials for production of the same by recombinant procedures. Fusion proteins are also disclosed which include extracellular .alpha..sub.d protein fragments, .alpha..sub.d I domain fragments or full length .alpha..sub.d polypeptides and human immunoglobulin constant regions. Binding molecules specific for .alpha..sub.d are also disclosed as useful for modulating the biological activities of .alpha..sub.d. DNA from other species which show homology to human .alpha..sub.d encoding sequences are also disclosed.

3 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

70. Document ID: US 5675060 A

Oct 7, 1997

Entry 70 of 88

File: USPT

US-PAT-NO: 5675060

DOCUMENT-IDENTIFIER: US 5675060 A

TITLE: Transgenic arthritic mice expressing a T-cell receptor transgene

DATE-ISSUED: October 7, 1997

INVENTOR-INFORMATION:

NAME

Benoist; Christophe O.
Mathis; Diane J.
Kouskoff; Valerie

CITY

Strasbourg
Strasbourg
Denver

STATE

N/A
N/A
CO

ZIP CODE

N/A
N/A
N/A

COUNTRY

FRX
FRX
N/A

US-CL-CURRENT: 800/3; 424/9.2, 800/9

ABSTRACT:

A transgenic animal model for arthritis is disclosed. The arthritic condition results from genetic (or immunologic) manipulations that result in the T cell receptor (TCR) repertoire of the animal being substantially limited relative to the TCR repertoire of a wildtype control animal. The TCR repertoire of the arthritic animal, albeit limited, is functionally viable. In a preferred embodiment, the invention relates to transgenic arthritic mice wherein arthritis results from (1) a transgenic allele which encodes and expresses TCR .alpha. and .beta. subunits that combine in T lymphocytes of the transgenic animal to form a TCR that recognizes an antigen comprising one or more epitopes of an oligopeptide derived from amino acids 41-61 of bovine pancreatic ribonuclease and/or (2) a polypeptide arthritogenic self antigens derived from endogenous proteins. The transgenic arthritic mice of the invention provides an animal model which faithfully mimics rheumatoid arthritis and by which human arthritogenic and therapeutic anti-arthritic compositions are evaluated. Also provided herein are therapeutic oligopeptides derived from the variable regions of the TCRs of the transgenes of the invention and/or from the amino acid sequence of proteins comprising endogenous polypeptide arthritogenic antigens.

17 Claims, 13 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KM/C	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

Oct 7, 1997

71. Document ID: US 5674487 A

File: USPT

Entry 71 of 88

US-PAT-NO: 5674487

DOCUMENT-IDENTIFIER: US 5674487 A

TITLE: Method for treating autoimmune diseases

DATE-ISSUED: October 7, 1997

INVENTOR-INFORMATION:

NAME

Smith; J. Bruce
Fort; John G.

CITY

Philadelphia
Glenview

STATE

PA
IL

ZIP CODE

19147
60025

COUNTRY

N/A
N/A

US-CL-CURRENT: 424/93.71; 424/93.7

ABSTRACT:

A method of treating autoimmune diseases is provided which involves administering an effective amount of allogeneic mononuclear cells or a molecule derived from these cells to an individual suffering from an autoimmune disease. Also provided are compositions for the treatment of autoimmune diseases.

5 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KM/C	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

72. Document ID: US 5635356 A

Jun 3, 1997

Entry 72 of 88

File: USPT

US-PAT-NO: 5635356

DOCUMENT-IDENTIFIER: US 5635356 A

TITLE: Anti-oncoimmunin-M antibodies and uses thereof

DATE-ISSUED: June 3, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Packard; Beverly	Rockville	MD	N/A	N/A
Komoriya; Akira	Rockville	MD	N/A	N/A

US-CL-CURRENT: 435/7.1; 530/350, 530/351, 530/387.3, 530/387.7, 530/388.23

ABSTRACT:

The present invention relates, in general, to oncoimmunins. In particular, the present invention relates to antibodies that specifically bind to a tumor-derived Oncoimmunin-myeloid (OI-M) factor that induces differentiation of myeloid cells. The invention also provides methods of detecting OI-M factors utilizing OI-M specific antibodies and immunodetection kits.

3 Claims, 40 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 25

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KWMC](#) | [Image](#)

73. Document ID: US 5625126 A

Apr 29, 1997

Entry 73 of 88

File: USPT

US-PAT-NO: 5625126

DOCUMENT-IDENTIFIER: US 5625126 A

TITLE: Transgenic non-human animals for producing heterologous antibodies

DATE-ISSUED: April 29, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lonberg; Nils	Redwood City	CA	N/A	N/A
Kay; Robert M.	San Francisco	CA	N/A	N/A

US-CL-CURRENT: 800/18; 536/23.1, 536/23.5, 536/23.53

ABSTRACT:

The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.

5 Claims, 110 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 89

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KWMC](#) | [Image](#)

74. Document ID: US 5614610 A

Mar 25, 1997

Entry 74 of 88

File: USPT

US-PAT-NO: 5614610
DOCUMENT-IDENTIFIER: US 5614610 A

TITLE: Tumor immunotherapy using anti-idiotypic antibodies

DATE-ISSUED: March 25, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hellstrom; Ingegerd	Seattle	WA	N/A	N/A
Hellstrom; Karl E.	Seattle	WA	N/A	N/A
Kahn; Maria S.	Seattle	WA	N/A	N/A
Beaton; Donna F.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 530/387.2; 530/388.25

ABSTRACT:

The present invention relates to methods which utilize anti-idiotypic antibodies, or fragments thereof, for tumor immunotherapy or immunoprophylaxis. Monoclonal anti-idiotypic antibodies which recognize an idioype present on a second antibody or on a T lymphocyte, or on an immune suppressor factor which is directed against a defined tumor antigen, can be used for immunization against a tumor, for immune anti-tumor activation or inhibition of suppression. The anti-idiotypic antibodies, or fragments thereof, can be used in adoptive immunotherapy. The anti-idiotypic antibodies, or fragments thereof, can also be used to monitor anti-antibody induction in patients undergoing passive immunization to a tumor antigen by administration of anti-tumor antibody. In another embodiment, administration of T lymphocytes which express an idioype directed against a defined tumor antigen can be used to transfer delayed-type hypersensitivity to the tumor. In another method of the invention, the induction of anti-idiotypic antibodies in vivo by administration of anti-tumor antibody or immune cells or factors exhibiting an anti-tumor idioype can be therapeutically valuable.

5 Claims, 55 Drawing figures
Exemplary Claim Number: 1

Number of Drawing Sheets: 19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

75. Document ID: US 5614192 A

File: USPT

Mar 25, 1997

Entry 75 of 88

US-PAT-NO: 5614192

DOCUMENT-IDENTIFIER: US 5614192 A

TITLE: T cell receptor peptides as therapeutics for immune-related disease

DATE-ISSUED: March 25, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandenbark; Arthur A.	Portland	OR	N/A	N/A

US-CL-CURRENT: 424/185.1; 424/184.1, 424/193.1, 514/12, 514/16, 514/2, 530/300, 530/324,
530/328, 530/868

ABSTRACT:

Peptides and pharmaceutical compositions comprising immunogenic peptides of a marker T cell receptor (TCR) characteristic of an immune-related disease, capable of preventing, suppressing, or treating the disease, are disclosed. In a preferred embodiment, the amino acid sequence of the peptide corresponds to at least part of the second complementarity determining region (CDR2) of the TCR. Antibodies and/or T cells immunologically reactive to the TCR peptide capable of preventing, suppressing, or treating an immune-related disease by passive transfer are also disclosed.

56 Claims, 47 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 27

76. Document ID: US 5614191 A

Mar 25, 1997

Entry 76 of 88

US-PAT-NO: 5614191

DOCUMENT-IDENTIFIER: US 5614191 A

TITLE: IL-13 receptor specific chimeric proteins and uses thereof

DATE-ISSUED: March 25, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Puri; Raj K.	North Potomac	MD	N/A	N/A
Debinski; Waldemar	Hummelstown	PA	N/A	N/A
Pastan; Ira	Potomac	MD	N/A	N/A
Obiri; Nicholas	Gaithersburg	MD	N/A	N/A

US-CL-CURRENT: 424/178.1; 424/134.1, 424/138.1, 424/183.1, 435/69.6, 435/7.23, 530/387.3,
530/387.7, 530/391.3, 530/391.7

ABSTRACT:

The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell. The method involves providing a chimeric molecule that comprises an effector molecule attached to a targeting molecule that specifically binds an IL-13 receptor and contacting a tumor cell with the chimeric molecule.

21 Claims, 0 Drawing figures

Exemplary Claim Number: 1

77. Document ID: US 5605689 A

Feb 25, 1997

Entry 77 of 88

US-PAT-NO: 5605689

DOCUMENT-IDENTIFIER: US 5605689 A

TITLE: Treatment of HIV-associated immune thrombocytopenic purpura

DATE-ISSUED: February 25, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ammann; Arthur J.	San Rafael	CA	N/A	N/A

US-CL-CURRENT: 424/134.1; 424/133.1, 424/148.1, 530/387.3, 530/388.35

ABSTRACT:

The invention relates to a method for treating HIV-associated immune thrombocytopenic purpura (ITP) which comprises administering to a patient in need of such treatment a therapeutically effective amount of a molecule comprising an amino acid sequence capable of binding to HIV.

7 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

78. Document ID: US 5576423 A

Nov 19, 1996

Entry 78 of 88

File: USPT

US-PAT-NO: 5576423
DOCUMENT-IDENTIFIER: US 5576423 A

TITLE: Antibodies to the slam protein expressed on activated T cells
DATE-ISSUED: November 19, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aversa; Gregorio	Palo Alto	CA	N/A	N/A
Chang; Chia-Chun J.	San Jose	CA	N/A	N/A
Cocks; Benjamin G.	Mountain View	CA	N/A	N/A
de Vries; Jan E.	Los Altos	CA	N/A	N/A

US-CL-CURRENT: 530/388.75, 424/154.1, 435/331, 435/343.2, 435/70.21, 530/387.9,
530/389.6, 530/391.3

ABSTRACT:

Purified genes which encode a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigen. Methods of using said reagents and diagnostic kits are also provided.
26 Claims, 0 Drawing figures
Exemplary Claim Number: 1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

79. Document ID: US 5556763 A

File: USPT

Sep 17, 1996

Entry 79 of 88

US-PAT-NO: 5556763

DOCUMENT-IDENTIFIER: US 5556763 A

TITLE: Evaluation and treatment of patients with progressive immunosuppression

DATE-ISSUED: September 17, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ochoa; Augusto C.	Frederick	MD	N/A	N/A
Longo; Dan L.	Kensington	MD	N/A	N/A
Ghosh; Paritosh	Frederick	MD	N/A	N/A
Young; Howard A.	Geithersburg	MD	N/A	N/A

US-CL-CURRENT: 435/7.23; 424/9.2, 424/93.71, 435/5, 435/7.24, 436/501

ABSTRACT:

A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels, T lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, a protein in the T lymphocyte signal transduction pathway, or of the NF-.kappa.B/rel family and comparing the level and pattern to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.
11 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

80. Document ID: US 5547853 A

Entry 80 of 88

US-PAT-NO: 5547853

DOCUMENT-IDENTIFIER: US 5547853 A

TITLE: CD2-binding domain of lymphocyte function associated antigen 3

DATE-ISSUED: August 20, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wallner; Barbara P.	Cambridge	MA	N/A	N/A
Miller; Glenn T.	Haverhill	MA	N/A	N/A
Rosa; Margaret D.	Winchester	MA	N/A	N/A

US-CL-CURRENT: 435/69.1, 435/252.3, 435/320.1, 435/69.7, 435/810, 436/86, 514/2, 530/350,

536/23.4, 536/23.5

ABSTRACT:

Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.

35 Claims, 47 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 31

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

Jun 25, 1996

81. Document ID: US 5529921 A

Entry 81 of 88

US-PAT-NO: 5529921

DOCUMENT-IDENTIFIER: US 5529921 A

TITLE: In vitro activation of cytotoxic t-cells using insect cells expressing human class I MHC and .beta.2-microglobulin

DATE-ISSUED: June 25, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Peterson; Per A.	La Jolla	CA	N/A	N/A
Jackson; Michael	Del Mar	CA	N/A	N/A
Langlade-Demoyen; Pierre	Del Mar	CA	N/A	N/A

US-CL-CURRENT: 435/375; 435/252.3, 435/320.1

ABSTRACT:

The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CD8 cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human .beta.2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.

12 Claims, 25 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 19

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

82. Document ID: US 5474771 A

Dec 12, 1995

Entry 82 of 88

US-PAT-NO: 5474771

DOCUMENT-IDENTIFIER: US 5474771 A

TITLE: Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same

DATE-ISSUED: December 12, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lederman; Seth	New York	NY	N/A	N/A
Chess; Leonard	Scarsdale	NY	N/A	N/A
Yellin; Michael J.	Riverdale	NY	N/A	N/A

US-CL-CURRENT: 424/133.1, 424/130.1, 424/144.1, 424/153.1, 424/154.1, 435/343.2,
435/70.21, 530/388.7, 530/388.73, 530/388.75

ABSTRACT:

This invention provides a monoclonal antibody which specifically recognizes and forms a complex with a protein located on the surface of activated T cells and thereby inhibits T cell activation of B cells. This invention also provides the monoclonal antibody 5c8 (ATCC Accession No. HB 10916).

This invention provides a human CD4.sup.- T cell leukemia cell line designated D1.1 (ATCC Accession No. CRL 10915) capable of constitutively providing contact-dependent helper function to B cells. This invention also provides an isolated protein from the surface of activated T cells, wherein the protein is necessary for T cell activation of B cells. This invention further provides an isolated, soluble protein from the surface of activated T cells, wherein the protein is necessary for T cell activation of B cells.

14 Claims, 66 Drawing figures

Exemplary Claim Number: 1,12

Number of Drawing Sheets: 20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

83. Document ID: US 5426029 A

Jun 20, 1995

Entry 83 of 88

File: USPT

US-PAT-NO: 5426029
DOCUMENT-IDENTIFIER: US 5426029 A

TITLE: Therapeutic and diagnostic methods using leukocyte surface antigens

DATE-ISSUED: June 20, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rittershaus; Charles W.	Malden	MA	N/A	N/A
Tian; Wei-Tao	Allston	MA	N/A	N/A
Kung; Patrick C.	Lexington	MA	N/A	N/A

US-CL-CURRENT: 435/7.21; 435/7.24, 435/7.9, 435/7.94, 436/501, 436/506, 436/518, 436/536

ABSTRACT:

The present invention is directed to the measurement of soluble leukocyte surface markers, soluble T cell growth factor receptors, soluble complement receptors, soluble T cell differentiation antigens, or related soluble molecules or fragments thereof, and the use of such measurements in the diagnosis and therapy of diseases and disorders. The invention is also directed to the measurement of soluble CD35 (sCD35) or fragments thereof, and the use of such measurements in detecting disease or disorders. A polyclonal sandwich assay is provided for the detection and/or measurement of soluble CD35. The invention further relates to the measurement of total leukocyte markers or fragments thereof, and the use of such measurements in the detection and diagnosis of diseases or disorders. The term "total" leukocyte marker used herein refers to the total amount of a leukocyte marker in a sample, including that present in membrane and intracellular compartments and extracellular soluble compartments. Measurements of a total leukocyte marker can be used to determine the approximate amount in a body fluid sample of leukocytes positive for the leukocyte marker. In a further embodiment, the invention relates to the measurement of both the amount of total leukocyte marker and the amount of the soluble form of the leukocyte marker and a comparison of the measured levels.

18 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMPC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

84. Document ID: US 5420264 A

File: USPT

May 30, 1995

Entry 84 of 88

US-PAT-NO: 5420264

DOCUMENT-IDENTIFIER: US 5420264 A

TITLE: Non-human primate CD4 polypeptides, human CD4 molecules capable of glycosylation, fragments thereof, fusion proteins thereof, genetic sequences thereof, and the use thereof

DATE-ISSUED: May 30, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seed; Brian	Boston	MA	N/A	N/A
Camerini; David	Los Angeles	CA	N/A	N/A

US-CL-CURRENT: 435/365; 435/243, 435/252.3, 435/320.1, 536/23.1, 536/23.4, 536/23.5, 536/23.53

ABSTRACT:

The present invention relates, in general, to substantially pure polynucleotide molecules specifying chimpanzee or rhesus monkey CD4, and fragments thereof and Gp120 binding molecules related to human CD4. The present invention further relates to polynucleotide molecules specifying CD4 fusion proteins and host cells containing the polynucleotide molecules.

7 Claims, 0 Drawing figures
Exemplary Claim Number: 1

85. Document ID: US 5329028 A

Jul 12, 1994

Entry 85 of 88

US-PAT-NO: 5329028

DOCUMENT-IDENTIFIER: US 5329028 A

TITLE: Carbohydrate-directed cross-linking reagents

DATE-ISSUED: July 12, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ashkenazi; Avi J.	San Mateo	CA	N/A	N/A
Chamow; Steven M.	San Mateo	CA	N/A	N/A
Kogan; Timothy P.	Sugar Land	TX	N/A	N/A

US-CL-CURRENT: 548/548; 548/546, 548/547, 548/549

ABSTRACT:

The invention is from the field of heterobifunctional cross-linking reagents. More particularly, the invention concerns cross-linking reagents which combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, thereby allowing coupling of aldehydes to free thiols.

13 Claims, 9 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 4

86. Document ID: US 5314813 A

May 24, 1994

Entry 86 of 88

US-PAT-NO: 5314813

DOCUMENT-IDENTIFIER: US 5314813 A

TITLE: Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines

DATE-ISSUED: May 24, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Peterson; Per A.	LaJolla	CA	N/A	N/A
Jackson; Michael	Del Mar	CA	N/A	N/A
Langlade-Demoyen; Pierre	Del Mar	CA	N/A	N/A

US-CL-CURRENT: 435/465; 435/320.1, 435/348

ABSTRACT:

The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CD8 cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human .beta.2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.

9 Claims, 24 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 19

87. Document ID: US 5223426 A

Jun 29, 1993

Entry 87 of 88

File: USPT

US-PAT-NO: 5223426

DOCUMENT-IDENTIFIER: US 5223426 A

TITLE: Monoclonal antibodies reactive with defined regions of the T-cell antigen receptor

DATE-ISSUED: June 29, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skibbens; Robert V.	Chapel Hill	NC	N/A	N/A
Henry; Larry D.	Brookline	MA	N/A	N/A
Rittershaus; Charles W.	Malden	MA	N/A	N/A
Tian; Wei-Tao	Allston	MA	N/A	N/A
Ip; Stephen H.	Sudbury	MA	N/A	N/A
Kung; Patrick C.	Lexington	MA	N/A	N/A
Snider; Mary Ellen	Ledyard	CT	N/A	N/A
Ko; Jone-Long	Cambridge	MA	N/A	N/A
Wood; Nancy L.	Cambridge	MA	N/A	N/A

US-CL-CURRENT: 435/331; 424/144.1, 424/154.1, 530/387.1, 530/387.9, 530/388.22,

530/388.75

ABSTRACT:

The present invention relates to monoclonal antibodies which recognize defined regions of the T-cell receptor (TCR). In a specific embodiment, the invention provides monoclonal antibodies which are reactive with a constant region of the alpha chain of the TCR. In particular embodiments, the invention relates to two monoclonal antibodies, termed .alpha.F1 and .alpha.F2, which react with two different epitopes on the framework region of the .alpha. monomer of the TCR molecule. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the beta chain of the TCR. In particular, the invention provides two monoclonal antibodies, termed W112 and 2D1, which react with .beta. chain variable regions V.beta.5.3 and V.beta.8.1, respectively. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the delta chain of the TCR. In particular, the invention provides monoclonal antibody .delta.TCS1, isotype IgG2a. The monoclonal antibodies of the invention have value in diagnosis and therapy and are useful tools for study of the immune system.

13 Claims, 23 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 24

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KOMC](#) | [Image](#)

88. Document ID: US 5185250 A

Feb 9, 1993

Entry 88 of 88

File: USPT

US-PAT-NO: 5185250
DOCUMENT-IDENTIFIER: US 5185250 A

TITLE: Human .gamma., .delta.T cell antigen receptor polypeptides and nucleic acids
DATE-ISSUED: February 9, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brenner; Michael B.	Sherborn	MA	N/A	N/A
Seidman; Jonathan	Milton	MA	N/A	N/A
Strominger; Jack L.	Lexington	MA	N/A	N/A
Ip; Stephen H.	Sudbury	MA	N/A	N/A
Krangel; Michael S.	Chapel Hill	NC	N/A	N/A
Band; Hamid	Boston	MA	N/A	N/A

US-CL-CURRENT: 435/69.3; 435/69.1, 435/7.24, 530/350, 530/387.9, 530/388.22, 530/388.75,
536/23.5

ABSTRACT:

The present invention is directed to purified polypeptides comprising the .gamma. T cell antigen receptor (TCR) polypeptide, the .delta. TCR polypeptide, a .gamma., .delta. TCR complex, or a fragment thereof containing an epitope. The invention also relates to nucleic acid sequences encoding such polypeptides, and subsequences thereof. In specific embodiments, the invention relates to nucleic acid sequences comprising variable, diversity, joining, or constant regions of the .delta. TCR gene sequence. The invention also relates to monoclonal antibodies specifically reactive with an epitope of the gamma or delta TCR polypeptides. In specific embodiments, these antibodies are reactive with the delta constant region, the delta variable region, or gamma constant region. Such antibodies can be identified by detecting co-modulation of the CD3 antigen. In another embodiment, the invention relates to compositions comprising substantially purified cells which express both a .gamma., .delta. TCR and the CD4 antigen. The invention also relates to a composition comprising cells which express a .gamma., .delta. TCR that is not associated with a CD3 complex.

25 Claims, 70 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 50

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KMC | Image

Term	Documents
27 AND 26	88

Display 200 Documents including document number 88

Display Format: REV Change Format

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers

Help | Logout